Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

Learn more about:
Related Clinical Trial
The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world Study Assessment of Cognitive Function, Fatigue and Health Related Quality of Life in Children With Beta Thalassemia Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT) The Prevelence of IVS 1-6 (T-C) [HBB:c.92 +6 T-C] Gene Mutation in Suspected Cases of β Thalassemia in Assiut University Hospitals Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) Study on the Effect of Different Risk Factors on the Growth Parameters of Thalassemic Patients in Assiut (AUCH) The Prevelence of HBB c.93-21 G-A in β Thalassemia Patients Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs) Thrombin Generation in Beta-thalassemia Major Iron Status in BTM With Blood Transfusion Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia Genetic Variants Affecting the Clinical Severity of Beta Thalassemia Association of Hb F Level With Clinical Severity of Beta Thalassemia Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients The Role of OCTA in Patients Affected by Beta Thalassemia

Brief Title

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

Official Title

A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent β-Thalassemia

Brief Summary

      This is a single-dose, open-label study in pediatric participants with TDT. The study will
      evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic
      stem and progenitor cells (hHSPCs) (CTX001).
    


Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Proportion of Participants who Achieve Transfusion Independence for at Least 12 Consecutive Months (TI12)

Secondary Outcome

 Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Condition

Beta-Thalassemia

Intervention

CTX001

Study Arms / Comparison Groups

 CTX001
Description:  CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants will receive single infusion of CTX001 through central venous catheter.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Biological

Estimated Enrollment

12

Start Date

May 3, 2022

Completion Date

May 2026

Primary Completion Date

May 2026

Eligibility Criteria

        Key Inclusion Criteria:

          -  Diagnosis of TDT as defined by:

               -  Documented homozygous or compound heterozygous β-thalassemia including
                  β-thalassemia/hemoglobin E (HbE). Participants can be enrolled based on
                  historical data, but a confirmation of the genotype using the study central
                  laboratory will be required before busulfan conditioning

               -  History of at least 100 mL/kilograms (kg)/year of packed RBC transfusions in the
                  prior 24 months before signing of consent (or the last rescreening for patients
                  going through repeat screening) or, for participants initiating transfusion
                  therapy <24 months before signing of consent, requirement for packed RBC
                  transfusion at least every 3 to 4 weeks for ≥6 months

          -  Eligible for autologous stem cell transplant as per investigator's judgment.

        Key Exclusion Criteria:

          -  A willing and healthy 10/10 human leukocyte antigen (HLA)-matched related donor is
             available per investigator's judgement

          -  Prior hematopoietic stem cell transplant (HSCT)

          -  Participants with associated α-thalassemia and >1 alpha deletion, or alpha
             multiplications

          -  Participants with sickle cell β-thalassemia variant

          -  Clinically significant and active bacterial, viral, fungal, or parasitic infection as
             determined by the investigator

        Other protocol defined Inclusion/Exclusion criteria may apply.
      

Gender

All

Ages

2 Years - 11 Years

Accepts Healthy Volunteers

No

Contacts

, 617-341-6777, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT05356195

Organization ID

VX21-CTX001-141

Secondary IDs

2021-002172-39

Responsible Party

Sponsor

Study Sponsor

Vertex Pharmaceuticals Incorporated

Collaborators

 CRISPR Therapeutics

Study Sponsor

, , 


Verification Date

April 2022